vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and INDEPENDENCE REALTY TRUST, INC. (IRT). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $165.3M, roughly 1.0× INDEPENDENCE REALTY TRUST, INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 2.5%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 2.2%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Brandywine Realty Trust is a Philadelphia-based real estate investment trust (REIT) that invests in office buildings in Philadelphia, Washington, D.C., and Austin, Texas.
ESPR vs IRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $165.3M |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | — |
| Revenue YoY | 143.7% | 2.5% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $165.3M | ||
| Q4 25 | $168.4M | $167.1M | ||
| Q3 25 | $87.3M | $167.1M | ||
| Q2 25 | $82.4M | $162.2M | ||
| Q1 25 | $65.0M | $161.2M | ||
| Q4 24 | $69.1M | $161.0M | ||
| Q3 24 | $51.6M | $160.1M | ||
| Q2 24 | $73.8M | $158.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $33.3M | ||
| Q3 25 | $-31.3M | $6.9M | ||
| Q2 25 | $-12.7M | $8.0M | ||
| Q1 25 | $-40.5M | $8.4M | ||
| Q4 24 | — | $-1.0M | ||
| Q3 24 | $-29.5M | $12.4M | ||
| Q2 24 | $-61.9M | $10.4M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | — | ||
| Q2 24 | 3.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 19.9% | ||
| Q3 25 | -35.9% | 4.1% | ||
| Q2 25 | -15.4% | 5.0% | ||
| Q1 25 | -62.2% | 5.2% | ||
| Q4 24 | — | -0.6% | ||
| Q3 24 | -57.2% | 7.7% | ||
| Q2 24 | -83.9% | 6.5% |
| Q1 26 | — | $0.00 | ||
| Q4 25 | $0.32 | $0.14 | ||
| Q3 25 | $-0.16 | $0.03 | ||
| Q2 25 | $-0.06 | $0.03 | ||
| Q1 25 | $-0.21 | $0.04 | ||
| Q4 24 | $-0.14 | $-0.01 | ||
| Q3 24 | $-0.15 | $0.05 | ||
| Q2 24 | $-0.33 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $23.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $3.4B |
| Total Assets | $465.9M | $6.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $23.3M | ||
| Q4 25 | $167.9M | $23.6M | ||
| Q3 25 | $92.4M | $23.3M | ||
| Q2 25 | $86.1M | $19.5M | ||
| Q1 25 | $114.6M | $29.1M | ||
| Q4 24 | $144.8M | $21.2M | ||
| Q3 24 | $144.7M | $17.6M | ||
| Q2 24 | $189.3M | $21.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.3B |
| Q1 26 | — | $3.4B | ||
| Q4 25 | $-302.0M | $3.5B | ||
| Q3 25 | $-451.4M | $3.5B | ||
| Q2 25 | $-433.5M | $3.4B | ||
| Q1 25 | $-426.2M | $3.5B | ||
| Q4 24 | $-388.7M | $3.4B | ||
| Q3 24 | $-370.2M | $3.4B | ||
| Q2 24 | $-344.2M | $3.4B |
| Q1 26 | — | $6.1B | ||
| Q4 25 | $465.9M | $6.0B | ||
| Q3 25 | $364.0M | $6.1B | ||
| Q2 25 | $347.1M | $6.0B | ||
| Q1 25 | $324.0M | $6.0B | ||
| Q4 24 | $343.8M | $6.1B | ||
| Q3 24 | $314.1M | $5.9B | ||
| Q2 24 | $352.3M | $5.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.66× | ||
| Q1 25 | — | 0.65× | ||
| Q4 24 | — | 0.68× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.66× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $282.1M | ||
| Q3 25 | $-4.3M | $79.3M | ||
| Q2 25 | $-31.4M | $82.2M | ||
| Q1 25 | $-22.6M | $60.4M | ||
| Q4 24 | $-35.0M | $259.8M | ||
| Q3 24 | $-35.3M | $69.2M | ||
| Q2 24 | $-7.2M | $83.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 8.48× | ||
| Q3 25 | — | 11.51× | ||
| Q2 25 | — | 10.22× | ||
| Q1 25 | — | 7.23× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 5.60× | ||
| Q2 24 | — | 8.02× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
IRT
| Rental and other property revenue | $165.2M | 100% |
| Other revenue | $109.0K | 0% |
